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INTRODUCTION
Patients who present with electrocardiograms (ECGs) 
demonstrating wide complex tachycardias (WCTs) are often 
challenging to clinicians. Not only may the patient present 
with (or be at risk for) hemodynamic compromise, but their 
treatment may result in hemodynamic collapse if the incorrect 
pharmacologic agent is selected. In Part 1 of this article,1 
the identification, epidemiology, and electrophysiology of 
WCTs were discussed. In this article, treatment of WCTs and 
miscellaneous causes of this condition will be described. 
In patients presenting with WCTs, correct interpretation 
of the ECG should not be the primary concern of emergency 
physicians.  In fact, it is appropriate (and may be preferred) 
to “diagnose” the ECG as “wide complex tachycardia of 
unknown (or uncertain) etiology.”  This may allow the 
treating clinician to focus on the patient and his or her 
hemodynamic status, rather than the academic exercise of 
ECG interpretation. The most important aspect of treating 
patients who present with WCTs is to select a therapeutic 
approach that does no harm. Several diagnostic algorithms 
were provided for the interpretation of WCTs, although none 
have proven superior over others, and great debate continues 
among researchers as to the preferred approach. Given 
this circumstance of uncertainty, proper treatment will be 
described for conditions resulting in WCTs.  
It is critical to note that once a WCT is identified, the 
Figure 1. ECG representing Wolff-Parkinson-White Syndrome (WPWS) with Atrial Fibrillation (AFIB). Note the wide QRS complexes, 
and the irregularly irregular rhythm. In lead II, the axis changes. A slurred delta wave can be identified in the left precordial leads, since 
the overall rate is not as fast as it might be when these conditions coexist. The R-R interval of the first two QRS complexes seen in 
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use of certain pharmacologic therapies may have deleterious 
effects on patients. Verapamil and diltiazem are calcium 
channel blockers (CCBs) that should be avoided in WCTs, 
as cardiac arrests from hemodynamic collapse have been 
reported following their administration.2,3 This is especially true 
in infants. Not only do these agents cause negative inotropy 
and at times profound vasodilation, but they may also allow 
WCTs to degenerate into VFIB. CCBs slow conduction at the 
AV node so that accessory pathways can be preferentially used; 
this results in ventricular rates that approach atrial rates. In 
addition, verapamil may shorten the effective refractory period 
of accessory pathway tissues, which is especially dangerous 
if AFIB and WPWS coexist (Figure 1). Digoxin should be 
avoided as well in the pharmacologic management of WCTs, 
as it may facilitate conduction via the accessory pathway. 
Shortening the refractory period of this pathway is particularly 
concerning in individuals with anterograde conduction over 
an accessory pathway (such as the case in AFIB with WPWS), 
as lethal ventricular rates may develop in response to fast or 
chaotic atrial rates. Propranolol (or other beta-blocking agents) 
may facilitate AV conduction via the accessory pathway, which 
can increase the ventricular rate to dangerous levels during 
AFIB. Lidocaine is no longer considered by the American 
Heart Association (AHA) as the drug of choice in WCTs of 
uncertain origin; good evidence supports alternative agents as 
being superior. If lidocaine is used, it should be administered 
with extreme caution, as it has been demonstrated to speed 
conduction through bypass tracts in experimental models. The 
use of oral agents in the emergency management of WCTs has 
no current therapeutic role. 
The clinical dictum “do no harm” is especially important 
when it comes to the management of WCTs, as delays to 
definitive therapy or their mismanagement (or both) can 
result in considerable morbidity and mortality. The patient’s 
clinical condition, not the ECG tracing, should be addressed 
and treated. If the patient is unstable without a pulse, this 
patient (and the WCT rhythm) should be treated as any 
patient in ventricular fibrillation, with defibrillation, airway 
management, and ACLS drugs according to current AHA 
algorithms. All unstable patients with a pulse should be treated 
using the unstable VT AHA algorithm, with consideration 
for sedation prior to synchronized cardioversion. The 
airway in these patients should be managed with appropriate 
aggressiveness. The amount of electrical energy needed to 
cardiovert this WCT to a stable rhythm is generally less than 
that required for VFIB.  In short, all undetermined WCTs 
should be treated as if they are ventricular in origin (VT). 
Unless the clinician is absolutely certain that the WCT is 
supraventricular in origin, pharmacologic agents used in the 
treatment of SVTs should not be administered (Table 1).
The use of adenosine as a rapid IV push in patients 
presenting with WCTs deserves special mention. This agent 
has tremendous efficacy converting SVTs, but on occasion 
has both diagnostic use as well as success converting some 
idiopathic causes of VT, especially cases originating in the 
fascicle.5,6 Adenosine should be used with caution in the 
diagnosis and management of WCTs, as prolonged AV block 
is likely to occur. The rapid administration of adenosine may 
help identify the underlying etiology of certain WCTs by 
slowing the heart rate or unmasking accessory tracts.7 Despite 
it being considered safe to use in patients presenting with 
WCTs,8 there are a few reports of complications following 
adenosine use. Adenosine may predispose the heart to atrial 
fibrillation, and may cause the cardiac rhythm to deteriorate 
into very rapid ventricular rates in patients with pre-excitation 
syndrome.9 Fortunately, this increase in ventricular rate was 
not shown to consistently cause hemodynamic deterioration 
in one study.10 Adenosine has also been reported to induce 
torsade de pointes11, and has proarrhythmic potential, 
especially in patients with aberrant conduction pathways, 
which may produce VT or other WCTs.12 Other authors 
share concern that the extranodal effects of adenosine may 
ultimately lead to pitfalls and misidentification of WCTs.13 The 
current AHA guidelines for tachycardia with pulses mentions 
the use of adenosine for regular wide QRS complexes if SVT 
with aberrancy is identified as the rhythm. It neither suggests 
nor recommends its use in a diagnostic trial.4 
In several areas of the 2005 AHA Tachycardia with 
pulses algorithm, “expert consultation” is either advised or 
should be considered. Once the patient is deemed clinically 
Table 1. Synopsis of Advanced Cardiac Life Support guidelines 
for Tachycardia with pulses algorithm4
Is the patient stable?
          A.   If NO, perform immediate synchronized cardioversion               
                (consider sedation), and obtain expert consultation.
          B.   If YES, assess QRS width and heart rate.
If QRS width greater than or equal to 0.12 seconds, assess if 
the rhythm is regular (and obtain expert consultation).
          A.   For regular WCTs, if VT or uncertain rhythm, 
                amiodarone; prepare for elective synchronized  
                cardioversion.  If SVT with aberrancy, treat with IV 
                adenosine (vagal maneuvers).
          B.   For irregular WCTs, if atrial fibrillation with aberrancy,     
                consider expert consultation; control rate.  If pre-      
                excited atrial fibrillation (AFIB + WPWS), expert  
                consultation is advised.  Avoid AV nodal blocking 
                agents, consider amiodarone.  If recurrent 
                polymorphic VT, seek expert consultation.  If torsade 
                de pointes, treat with IV magnesium.
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stable, and a candidate for pharmacologic intervention, the 
determination of regular versus irregular rhythm is necessary. 
For regular rhythms, any VT or uncertain rhythm should, 
according to the guidelines, be treated with IV amiodarone, 
with preparation for elective synchronized cardioversion (as 
long as the patient remains clinically stable). For patients 
with SVT with aberrant conduction, adenosine is suggested. 
If, on the other hand, the WCT is irregular, pharmacologic 
therapy depends on whether or not AFIB with aberrancy (in 
which diltiazem or beta-blockers are appropriate) or AFIB 
with WPWS (in which amiodarone is the agent of choice, and 
AV nodal blocking agents [e.g., adenosine, digoxin, diltiazem, 
verapamil] should be avoided) is most likely. According to the 
2006 Guidelines for the Management of Patients with Atrial 
Fibrillation published in Circulation, “… in hemodynamically 
stable patients with pre-excitation, type I antiarrhythmic 
agents or amiodarone may be administered intravenously.”  
These guidelines further state that if the dysrhythmia causes 
hemodynamic compromise, early direct current cardioversion 
is indicated.14  
Torsade de pointes is a special type of WCT, during 
which the electrical axis “twists” around the horizontal axis 
(Figure 2). It is categorized as a form of polymorphic VT. 
Cycles of alternating electrical polarity of the QRS complexes 
occur about the isoelectric axis. Torsade de pointes can be 
initiated when a premature ventricular contraction (PVC) 
falls on the T wave, or by ventricular couplets or triplets. 
It commonly has a long-short initiation sequence, and may 
be more likely during episodes of bradycardia.15 It has been 
associated with prolonged QT syndrome, multiple electrolyte 
abnormalities, many antiarrhythmic agents (ibutilide, sotalol, 
and the Class Ia agents, for example), phenothiazines, TCAs, 
Table 2. Miscellaneous causes of WCTs1,19
Torsade de pointes (Polymorphic VT)
Pacemaker-mediated tachycardia (PMT)
Drug overdose (digitalis, TCAs, lithium,20 cocaine,21,22,23 
diphenhydramine24)
Sodium channel blocking agents25
Hyperkalemia
Post-resuscitation
Malingering26 and/or ECG artifact27
Table 3. Summary pearls for Wide Complex Tachycardias
Interpretation of ECGs demonstrating WCTs should be  • 
based on clinical circumstances, not the ECG itself.
Although many algorithms and diagnostic criteria exist  • 
to help clinicians correctly interpret WCTs, these are 
not foolproof.  Therefore, clinicians must be comfortable 
accepting an interpretation of an ECG representing a WCT 
as “WCT of uncertain etiology.”  It is important to consider 
this when selecting therapies for patients presenting 
with WCTs, as some therapies can cause hemodynamic 
compromise or cardiovascular collapse.
Clues may be found in a patient’s previous ECG, or from  • 
capture and/or fusion beats identified in the ECG or rhythm 
strip.  AV dissociation (if identified) makes the diagnosis of 
VT much more likely.
In patients with structural heart disease, especially older  • 
patients with previous MIs or previous episodes of VT, the 
diagnosis of VT is far more likely and should be considered 
until proven otherwise.
Figure 2.  Torsade de pointes (polymorphic VT) captured on 12-lead ECG.  The baseline literally “twists of the points.” Treatment is with 
intravenous magnesium, and possibly overdrive pacing (Image courtesy Jeff A. Tabas, MD). Used with permission, ACEP.
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and pentamidine.16,17 In addition to withdrawing the causative 
agent and correcting electrolyte abnormalities, pharmacologic 
treatment is with a loading dose of IV magnesium sulfate, 
followed by infusion. Isoproterenol is no longer recommended 
as treatment for torsade de pointes, as it increases myocardial 
oxygen consumption and the likelihood for rhythm 
disturbances. Overdrive pacing to a heart rate of 90 - 130 beats 
per minute is generally successful in terminating torsade de 
pointes if it does not respond to magnesium.
It should be noted that neither lidocaine nor procainamide 
appear in these updated 2005 AHA ACLS treatment algorithm 
flow diagrams. Procainamide and sotalol do appear in the 
accompanying text as alternative drugs for wide complex 
regular tachycardias.18
Miscellaneous WCTs
Several additional causes of WCTs should be considered 
when evaluating and treating individuals presenting with 
Figure 3.  Permanent transvenous pacemaker results in wide QRS complexes. 
Figure 4.  Hyperkalemia causing a WCT in a patient with chronic renal failure (K+ 9.1).  The patient’s heart rate is 108 bpm, the QRS 
duration is 134 msec.  Note the prominent, narrow peaked T waves (esp. V2, V3), which, with historical factors, should help identify this 
diagnosis.
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ECGs demonstrating WCTs (Table 2). Hemodynamic stability 
remains the main principle directing patient management. 
These additional causes of WCTs have markedly different 
treatment strategies, depending on their etiologies.
Pacemaker-mediated tachycardias can be investigated 
using a pacemaker magnet over the pacemaker generator. 
As transvenous pacemaker leads are placed in the right 
ventricle, the QRS complexes generated by the pacemaker are 
widened. Any pacemaker-mediated tachycardias will therefore 
be WCTs. Adenosine may elicit hidden atrial activity, and 
it is particularly safe as the pacemaker should respond if 
prolonged AV block or a brief period of asystole occurs. With 
newer pacemakers, this condition is less common.28 Figure 3 
demonstrates a wide complex tachycardia in a patient with a 
pacemaker, although not pacemaker-mediated.
Tricyclic antidepressant (TCA) overdose causes a WCT 
due to the quinidine-like effects of these drugs. The class IA 
sodium channel blocking activity widens the QRS complex, 
with tachycardia being part of the toxidrome caused by these 
agents.  A high index of suspicion should help identify this 
clinical scenario. Treatment is with IV bicarbonate, aggressive 
airway protection, and supportive measures. Agents with 
similar properties have been reported to result in WCTs due 
to quinidine-like effects on the sodium channels, especially in 
toxic ingestions or overdoses.
Severe hyperkalemia may present with WCT as a late 
ECG manifestation of this condition (Figure 4). A high index 
of suspicion should cause one to consider this etiology, 
especially in the setting of renal failure. Initial treatment 
includes IV calcium to stabilize the myocardium, IV 
bicarbonate, IV glucose and insulin, and inhaled albuterol. An 
additional therapeutic regimen includes sodium polystyrene 
sulfonate (Kayexalate) resin, although this treatment does not 
take immediate effect and can be challenging to administer. 
Figure 5a.  Bidirectional ventricular tachycardia due to digitalis toxicity.  From: Piccini J, Zaas A. Images of Osler: Cases from the Osler 
Medical Service at Johns Hopkins University. Am J Med 2003 Jul;115(1):70-1. Used with permission.
Figure 5b.  12-lead ECG from a different patient demonstrating bidirectional ventricular tachycardia from digitalis toxicity.  The axes 
of the RBBB-morphology QRS complexes alternate.  From: Kummer JL, Nair R, Krishnan SC. Images in cardiovascular medicine. 
Bidirectional ventricular tachycardia caused by digitalis toxicity. Circ 2006 Feb 21;113(7):e156-7. Used with permission. 
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Emergent hemodialysis is the definitive treatment for acute 
hyperkalemia with WCT, and should be arranged as quickly as 
possible.
Severe digitalis overdose can cause a bidirectional 
VT.29,30,31 This WCT generally has a RBBB pattern, with 
the QRS complexes alternating between right and left axis 
deviation in the limb leads. This distinct pattern of alternating 
axis deviation is due to alternating impulse formation in 
the left posterior and left anterior fascicles (Figures 5a, b). 
Again, a high index of suspicion should assist in making 
this diagnosis, as individuals with severe digitalis overdose 
may have symptoms such as visual changes (especially color 
vision), changes in behavior, gastrointestinal disturbances, 
and access to this medication. This condition is more likely in 
elderly patients with mild dehydration or renal insufficiency, 
or in individuals following overdose. Treatment includes 
withdrawal of the offending agent and supportive care; 
definitive therapy is administration of digitalis-specific 
antibodies.    
SUMMARY
The treatment of patients presenting with wide complex 
tachycardias should be based on the clinical or hemodynamic 
status of the individual, not the ECG. The ECG in WCTs 
is not always helpful in determining the etiology of the 
rhythm disturbance. It may not even have clinical relevance 
in the emergent setting.32,33,34 None of the sets of diagnostic 
criteria described previously has proven to have 100% 
accuracy.  Therefore, clinicians should always treat the 
patient, not the ECG, when managing patients presenting with 
WCTs. Unstable patients require defibrillation or emergent 
cardioversion (with sedation considered). Pharmacologic 
treatment of stable patients should occur according to the most 
updated AHA ACLS guidelines, with “expert consultation” 
advised. As research continues, newer pharmacologic agents 
and treatment modalities are likely to become more common 
in the ED setting.
When the ECG diagnosis of a WCT is uncertain, 
clinicians should consider it to be VT and treat it as 
such.  Even given referral bias, the literature consistently 
identifies VT to be much more likely than SVT with aberrant 
conduction, which makes up part of the rationale behind this 
recommendation. More important, however, is that treating 
WCTs of uncertain etiology as rhythms originating above 
the ventricle may result in clinical deterioration, including 
cardiovascular collapse. Clinicians should be familiar with 
agents to avoid when treating individuals who present with 
WCTs. Furthermore, some pharmacologic agents used to treat 
VT may in fact terminate a WCT of supraventricular origin. 
Finally, clinicians must remain vigilant when evaluating and 
managing patients presenting with WCTs. They must look 
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Figure 6.  Example of an unusual WCT known as Idiopathic (benign) Ventricular Tachycardia.  This is caused by a re-entry loop in 
the apex of the LV, resulting in the left superior axis and RBBB pattern.  Also called Left Ventricular Tachycardia, it often responds to 
Verapamil. (Note -- CCBs should not be used in WCTs unless recommended by a cardiologist or electrophysiologist.) Volume IX, n o . 2  :  May 2008                                                 103                               The Western Journal of Emergency Medicine 
for ECGs demonstrating irregular wide QRS complexes, 
as such ECGs may represent atrial fibrillation with Wolff-
Parkinson-White Syndrome (WPWS). Caution should be 
maintained in patients presenting with a fast, irregular, wide-
complex rhythm, as serious consequences may occur from 
its misidentification or the use of pharmacologic agents that 
decrease refractory periods in or speed conduction through 
alternative pathways.
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